Autonomix Medical, Inc. - AMIX STOCK NEWS

Autonomix Medical (NASDAQ: AMIX) shared preliminary positive results from its proof-of-concept human clinical trial targeting pancreatic cancer pain. In a recent Virtual Investor segment, Dr. Robert Schwartz detailed the results from the first five lead-in patients and discussed the advancements in pain management techniques with fewer side effects. The trial focuses on the safety and effectiveness of transvascular energy delivery to ablate nerves causing pain. Early indications suggest significant improvements in patient quality of life. For further details, the company has made patient testimonials and the segment available online.

Autonomix announced positive results from the first five patients in its ongoing proof-of-concept human clinical trial for pain management in pancreatic cancer patients.

Key findings include: 60% of subjects experienced a mean 6.33 reduction in pain on the VAS pain scale, and 100% of responders saw clinically meaningful pain relief at 7 days post-procedure.

Responder patients reported a mean 78% improvement in quality of health and a 45% improvement in quality of life at 7 days post-procedure. The trial aims to complete enrollment by the end of 2024, and management will host a webcast to discuss the results.

Autonomix Medical (NASDAQ: AMIX) has appointed Brad Hauser as its new President and CEO, effective immediately. Hauser, who has over 20 years of experience in medical technology innovation, succeeds Lori Bisson, now the Executive Vice Chairman of the Board. Hauser's background includes key roles in companies such as Beauty Health, Soliton, ZELTIQ Aesthetics, and Allergan Aesthetics. At Autonomix, he aims to advance the company's mission of revolutionizing the diagnosis and treatment of nervous system diseases. The board has approved an inducement stock option grant of 900,000 shares to Hauser as part of his compensation package.

Autonomix will reveal preliminary topline results from the first five patients in its human clinical trial on June 18, 2024. This trial evaluates the safety and effectiveness of transvascular energy to ablate problematic nerves and reduce pain in pancreatic cancer patients. The announcement will be accompanied by a live webcast at 8:30 a.m. ET on the same day. Interested parties can register and access the webcast on the Autonomix website, which will archive the event for 90 days.

Autonomix Medical (NASDAQ: AMIX) announced the approval of a protocol amendment by the Ethics Committee for its ongoing proof-of-concept human clinical trial. The trial evaluates the safety and efficacy of delivering transvascular energy to ablate nerves and mitigate pain in pancreatic cancer patients. Following the treatment of the first five 'lead-in' patients, the protocol was amended to gather additional data on tumor encroachment and other bio-measurements, and to refine inclusion criteria based on patient-reported pain levels. Autonomix plans to release topline results from the lead-in patients soon and aims to complete trial enrollment by year-end. The company's catheter-based technology seeks to offer a targeted, effective alternative to current pain management methods.

Autonomix Medical (NASDAQ: AMIX) reported its FY2024 financials and corporate updates. Highlights include a net loss of $15.4M, up from $2.0M in FY2023, and an IPO raising $11.2M gross. The company has $8.6M cash on hand, sufficient to fund operations until Q1 2025. Key achievements involve the initiation of PoC human trials for RF ablation in pancreatic cancer pain, partnerships, and significant patent issuances. Clinical milestones set for 2024 include topline results from the first five PoC study patients in June and device design completion for clinical use. G&A and R&D expenses rose significantly due to IPO-related costs and clinical advancements.

Autonomix Medical announced the successful completion of a preclinical animal study demonstrating that targeted nerve ablation can significantly reduce tumor mass growth and metastases in pancreatic cancer. The study, involving mice injected with human pancreatic tumor cells, showed a 60% reduction in local invasion and a 40% decrease in liver metastases in the experimental group treated with peri-pancreatic neural ablation compared to the control group. CEO Lori Bisson highlighted these findings as supportive of the theory that nerve fibers contribute to cancer metastasis and emphasized potential future clinical applications. The company's technology aims to provide a more precise and effective alternative to current treatments for pancreatic cancer-related pain.

Autonomix Medical (NASDAQ: AMIX), a company specializing in medical devices for nervous system diseases, will participate in the Virtual Investor Closing Bell Series on May 16, 2024, at 4:00 PM ET. CEO Lori Bisson will present a corporate overview and business outlook. The event will be live-streamed on the company's website, with an opportunity for live questions from investors. A replay will be available for 90 days post-event.

Autonomix Medical, Inc. (NASDAQ: AMIX) has partnered with NoiseFigure Research, Inc. to enhance its ASIC microchip for human clinical testing and commercial production. The collaboration aims to revolutionize nerve system disease diagnosis and treatment. The proprietary ASIC technology promises superior nerve signal detection and localization, with 3000 times greater sensitivity than existing solutions. Autonomix's catheter-based technology targets neural signals associated with pain or disease, offering a more precise and effective alternative to current treatment methods. The initial focus is on addressing pancreatic cancer-related pain.